| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.23 | 0.02 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.068 | 0.02 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.064 | 0.02 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.03 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |